Evidence map›Paper›PMID 36328937›Full record

ArticleAdvances in biological regulation2022

Understanding the exceptional pre-vaccination Era East Asian COVID-19 outcomes.

Jay Bhattacharya, Phillip Magness, Martin Kulldorff

Abstract read
In one paragraph

Article in Advances in biological regulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Reassessing Early COVID-19 Strategies in East Asia: Insights From Japan and Korea.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2026
    Review
  2. Excess Deaths in Korea During the COVID-19 Pandemic: 2020-2022.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jay BhattacharyaStanford University School of Medicine, National Bureau of Economic Research, USA. Electronic address: jay@stanford.edu.
Phillip MagnessAmerican Institute for Economic Research, USA.
Martin KulldorffBrownstone Institute, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the first year of the pandemic, East Asian countries have reported fewer infections, hospitalizations, and deaths from COVID-19 disease than most countries in Europe and the Americas. Our goal in this paper is to generate and evaluate hypothesis that may explain this striking fact. We consider five possible explanations: (1) population age structure (younger people tend to have less severe COVID-19 disease upon infection than older people); (2) the early adoption of lockdown strategies to control disease spread; (3) genetic differences between East Asian population and European and American populations that confer protection against COVID-19 disease; (4) seasonal and climactic contributors to COVID-19 spread; and (5) immunological differences between East Asian countries and the rest of the world. The evidence suggests that the first four hypotheses are unlikely to be important in explaining East Asian COVID-19 exceptionalism. Lockdowns, in particular, fail as an explanation because East Asian countries experienced similarly good infection outcomes despite vast differences in lockdown policies adopted by different countries to control the COVID-19 epidemic. The evidence to date is consistent with our fifth hypothesis - pre-existing immunity unique to East Asia - but there are still essential parts of this story left for scientists to check.

Indexed as

COVID-19AgedCommunicable Disease ControlHumansPandemicsVaccinationCOVID-19East AsiaImmunityLockdown

Identifiers

PMID36328937
PMCPMC9575551

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.